Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-κB/NLRP3 signaling pathway

Abstract

The role of NF-κB and the NLRP3 inflammasome in the chronic inflammatory microenvironment of non-alcoholic steatohepatitis (NASH) has been posited as crucial. The Yanggan Jiangmei Formula (YGJMF) has shown promise in ameliorating hepatic steatosis in NASH patients, yet its pharmacological mechanisms remain largely unexplored. This study was conducted to investigate the efficacy of YGJMF in NASH and to elucidate its pharmacological underpinnings. To simulate NASH both in vivo and in vitro, high-fat-diet (HFD) rats and HepG2 cells stimulated with free fatty acids (FFAs) were utilized. The severity of liver injury and lipid deposition was assessed using serum indicators, histopathological staining, micro-magnetic resonance imaging (MRI), and the liver-to-muscle signal intensity ratio (SIR_L/M). Furthermore, a combination of enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), immunofluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting analyses was employed to investigate the NF-κB/NLRP3 signaling pathway and associated cytokine levels. The results from liver pathology, MRI assessments, and biochemical tests in rat models demonstrated YGJMF’s significant effectiveness in reducing liver damage and lipid accumulation. Additionally, YGJMF markedly reduced hepatocyte inflammation by downregulating inflammatory cytokines in both liver tissue and serum. Furthermore, YGJMF was found to disrupt NF-κB activation, consequently inhibiting the assembly of the NLRP3 inflammasome in both the in vitro and in vivo models. The preliminary findings of this study suggest that YGJMF may alleviate hepatic steatosis and inhibit the NF-κB/NLRP3 signaling pathway, thereby exerting anti-inflammatory effects in NASH.

Keywords

Non-alcoholic steatohepatitis / Nuclear factor kappa B / NLRP3 inflammasome / Yanggan Jiangmei Formula

References

[1] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.

[2] Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1.

[3] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048.

[4] Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB[J]. Nat Med, 2005, 11(2): 183-190.

[5] Afonina IS, Zhong Z, Karin M, et al. Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome[J]. Nat Immunol, 2017, 18(8): 861-869.

[6] Swanson KV, Deng M, Ting JP, The NLRP3 inflammasome: molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489.

[7] Paik S, Kim JK, Silwal P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation[J]. Cell Mol Immunol, 2021, 18(5): 1141-1160.

[8] Jo EK, Kim JK, Shin DM, et al. Molecular mechanisms regulating NLRP3 inflammasome activation[J]. Cell Mol Immunol, 2016, 13(2): 148-159.

[9] Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling[J]. Nat Rev Immunol, 2016, 16(7): 407-420.

[10] Calcagno DM, Chu A, Gaul S, et al. NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH[J]. Hepatology, 2022, 76(3): 727-741.

[11] Wallert M, Börmel L, Lorkowski S. Inflammatory diseases and vitamin E-what do we know and where do we go?[J]. Mol Nutr Food Res, 2021, 65(1): e2000097.

[12] Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68(1): 361-371.

[13] Yao H, Qiao YJ, Zhao YL, et al., Herbal medicines and nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2016, 22(30): 6890-6905.

[14] Gao W, Chen Q, Sun L. Professor Jin Shi’s experience in the treatment of chronic hepatitis B with elevated AST[J]. Chin J Ethnomed Ethnopharm, 2021, 30(20): 85-87.

[15] Wu Y, Kuang Y, Wu Y, et al. Yang-Gan-Jiang-Mei formula alleviates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome through mitophagy[J]. Biotechnol Genet Eng Rev, 2023: 1-20.

[16] Zhu G, Chen L, Liu S, et al. Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats[J]. Heliyon, 2022, 8(7): e09872.

[17] Tang K, Deng Y, Zheng C, et al. Prevention of nonalcoholic hepatic steatosis by Shenling Baizhu Powder: involvement of adiponectin-induced inhibition of hepatic SREBP-1c[J]. Oxid Med Cell Longev, 2020, 2020: 9701285.

[18] Wang Y, Chen C, Chen J, et al. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation[J]. Redox Biol, 2022, 52: 102322.

[19] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-21.

[20] Zhou J, Zhang X, Wan L, et al. Zi Qi decoction alleviates liver fibrosis by inhibiting the toll-like receptor 4 (TLR4)-related nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways[J]. Med Sci Monit, 2021, 27: e929438.

[21] Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice[J]. J Hepatol, 2016, 65(5): 1006-1016.

[22] Balassy C, Feier D, Peck-Radosavljevic M, et al. Susceptibility-weighted MR imaging in the grading of liver fibrosis: a feasibility study[J]. Radiology, 2014, 270(1): 149-158.

[23] Asanuma T, Ono M, Kubota K, et al. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease[J]. Gut, 2010, 59(2): 258-266.

[24] de Carvalho Ribeiro M, Szabo G. Role of the inflammasome in liver disease[J]. Annu Rev Pathol, 2022, 17: 345-365.

[25] Duan Y, Pan X, Luo J, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298.

[26] Akbari R, Behdarvand T, Afarin R, et al. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis[J]. BMC Pharmacol Toxicol, 2021, 22(1): 53.

[27] Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease[J]. Circ Res, 2005, 96(9): 939-949.

[28] Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor[J]. Clin Chim Acta, 2007, 380(1-2): 24-30.

[29] Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(48): 18070-18091.

[30] Ying Y, Zhang H, Yu D, et al. Gegen Qinlian decoction ameliorates nonalcoholic fatty liver disease in rats via oxidative stress, inflammation, and the NLRP3 signal axis[J]. Evid-Based Compl Alt, 2021, 2021: 6659445.

[31] Yang Y, Sheng Y, Wang J, et al., Double-negative T cells regulate hepatic stellate cell activation to promote liver fibrosis progression via NLRP3[J]. Front Immunol, 2022, 13: 857116.

[32] Wang Q, Ou Y, Hu G, et al. Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice[J]. Br J Pharmacol, 2020, 177(8): 1806-1821.

[33] Ralston JC, Lyons CL, Kennedy EB, et al. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues[J]. Annu Rev Nutr, 2017, 37: 77-102.

[34] Schroder K, Tschopp J. The inflammasomes[J]. Cell, 2010, 140(6): 821-832.

[35] Mirea AM, Tack CJ, Chavakis T, et al. IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies[J]. Trends Mol Med, 2018, 24(5): 458-471.

[36] Ghezelbash B, Shahrokhi N, Khaksari M, et al. Protective roles of Shilajit in modulating resistin, adiponectin, and cytokines in rats with non-alcoholic fatty liver disease[J]. Chin J Integr Med, 2022, 28(6): 531-537.

[37] Guan X, Shen S, Liu J, et al. Protective effecs of baicalin magnesium on non-alcoholic steatohepatitis rats are based on inhibiting NLRP3/Caspase-1/IL-1β signaling pathway[J]. BMC Complement Med Ther, 2023, 23(1): 72.

[38] Anand PK. Lipids, inflammasomes, metabolism, and disease[J]. Immunol Rev, 2020, 297(1): 108-122.

[39] Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol, 2018, 68(2): 280-295.

[40] Shi C, Yang H, Zhang Z. Involvement of nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome in the pathogenesis of liver diseases[J]. Front Cell Dev Biol, 2020, 8: 139.

[41] Hu M, Zhang D, Xu H, et al. Salidroside activates the AMP-activated protein kinase pathway to suppress nonalcoholic steatohepatitis in mice[J]. Hepatology, 2021, 74(6): 3056-3073.

[42] Zheng T, Yang X, Li W, et al. Salidroside attenuates high-fat diet-induced nonalcoholic fatty liver disease via AMPK-dependent TXNIP/NLRP3 pathway[J]. Oxid Med Cell Longev, 2018, 2018: 8597897.

[43] Feng J, Chen K, Xia Y, et al. Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways[J]. Drug Des Devel Ther, 2018, 12: 1837-1853.

[44] Gong L, Wang C, Zhou H, et al. A review of pharmacological and pharmacokinetic properties of Forsythiaside A[J]. Pharmacol Res, 2021, 169: 105690.

[45] Wang X, Shi L, Wang X, et al. MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver diseasevia modulating the gut-liver axis[J]. Int J Biol Macromol, 2019, 141: 1013-1021.

[46] Xiao J, Liong EC, Ching YP, et al. Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury[J]. Nutr Diabetes, 2013, 3(7): e81.

[47] Miao H, Ouyang H, Guo Q, et al. Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism[J]. J Nutr Biochem, 2022, 106: 109020.

[48] Yi H, Peng H, Wu X, et al. The therapeutic effects and mechanisms of quercetin on metabolic diseases: pharmacological data and clinical evidence[J]. Oxid Med Cell Longev, 2021, 2021: 6678662.

[49] Li Q, Tan JX, He Y, et al. Atractylenolide III ameliorates non-alcoholic fatty liver disease by activating hepatic adiponectin receptor 1-mediated AMPK pathway[J]. Int J Biol Sci, 2022, 18(4): 1594-1611.

[50] Fan Y, Dong W, Wang Y, et al. Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 959495.

Funding

National Natural Science Foundation of China(8200151236)

Postgraduate Research Practice Innovation Program of Jiangsu Province(KYCX22_1903)

Outstanding Clinical Talents of Traditional Chinese Medicine in Jiangsu Province(Jiangsu Science)

Outstanding Clinical Talents of Traditional Chinese Medicine in Jiangsu Province(Education of Traditional Chinese Medicine [2017])